Frederick Feuerbach
Cardiovascular Disease · New York, NYNPI 1639167117
Payments from drug & device makers
Across 75 payments — averaging $25.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$370
- Boehringer Ingelheim$185
- Regeneron Healthcare Solutions, Inc.$162
- Amgen$156
- Novartis$121
- Amarin Pharma, Inc.$106
- plus $798 from 19 others
What the payments were for
- Food & beverage$1,79495%
- Education$1035%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 2 | $370 |
| Boehringer Ingelheim | 17 | $185 |
| Regeneron Healthcare Solutions, Inc. | 6 | $162 |
| Amgen | 7 | $156 |
| Novartis | 6 | $121 |
| Amarin Pharma, Inc. | 5 | $106 |
| Lilly USA, LLC | 5 | $85 |
| Baxter Healthcare | 1 | $84 |
| E.r. Squibb & Sons, L.L.C. | 3 | $81 |
| Sanofi-aventis U.S. LLC | 3 | $70 |
| Heartflow, Inc. | 3 | $52 |
| Johnson & Johnson | 2 | $48 |
| Scpharmaceuticals Inc. | 1 | $41 |
| AstraZeneca | 2 | $41 |
| Biobeat USA Inc. | 1 | $39 |
| GSK | 2 | $37 |
| Novo Nordisk | 1 | $34 |
| Philips North America LLC | 1 | $32 |
| Cleerly, Inc. | 1 | $28 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Lantheus Medical Imaging, Inc. | 1 | $20 |
| Gilead | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,897 in reported general payments places this provider in the 50th percentile of 2,302 cardiovascular disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 162 | $167,218 |
| XareltoRivaroxaban | 41 | $41,970 |
| MultaqDronedarone Hcl | 24 | $24,314 |
| EntrestoSacubitril/Valsartan | 28 | $21,575 |
| Praluent PenAlirocumab | 21 | $19,489 |
| Repatha SureclickEvolocumab | 13 | $19,020 |
| OzempicSemaglutide | 17 | $13,235 |
| MyrbetriqMirabegron | 21 | $9,352 |
| AmbienZolpidem Tartrate | 11 | $7,018 |
| Ezetimibe | 163 | $5,688 |
| Metoprolol Succinate | 201 | $3,898 |
| Rosuvastatin Calcium | 245 | $3,590 |
| Atorvastatin Calcium | 213 | $2,543 |
| Olmesartan Medoxomil | 70 | $1,784 |
| SynthroidLevothyroxine Sodium | 21 | $1,670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $48 | $41,97041 claims |
| Sanofi-aventis U.S. LLCMultaq, Ambien | $70 | $31,33135 claims |
| NovartisEntresto | $121 | $21,57528 claims |
| Novo NordiskOzempic | $34 | $13,23517 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $9,35221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in New York
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Gregg StoneNew York$3.7M
- Valentin FusterNew York$2.9M
- Tamim NazifNew York$2.2M
- Howard WeintraubNew York$1.7M
- Anuradha Lala-TrindadeNew York$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.